Clonal Hematopoiesis in Cancer Predisposition Syndromes

Overview

Journal Int J Hematol

Specialty Hematology

Date 2024 Dec 6

PMID 39643764

Authors

Kenichi Yoshida

Affiliations

Soon will be listed here.

Abstract

After recent advances in sequencing technologies led to the discovery of novel genes associated with predisposition to hematological malignancies, studies have now shown that myeloid neoplasms associated with germline variants are more common than previously estimated. Based on these findings, myeloid neoplasms with germline predisposition have emerged as a unique category in the recent World Health Organization classification of Haematolymphoid Tumors. Clonal hematopoiesis is common in healthy individuals, particularly in older people. In patients with germline predisposition to hematological malignancies, clonal hematopoiesis is frequently observed at younger ages and is often associated with unique disease-specific driver mutations, some of which are hypothesized to compensate for the inherited defect. This review summarizes recent findings on clonal hematopoiesis in cancer predisposition syndromes.

References

Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-405. DOI: 10.1182/blood-2016-03-643544. View

Makishima H, Saiki R, Nannya Y, Korotev S, Gurnari C, Takeda J . Germ line DDX41 mutations define a unique subtype of myeloid neoplasms. Blood. 2022; 141(5):534-549. PMC: 10935555. DOI: 10.1182/blood.2022018221. View

Feurstein S, Trottier A, Estrada-Merly N, Pozsgai M, McNeely K, Drazer M . Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages. Blood. 2022; 140(24):2533-2548. PMC: 9918848. DOI: 10.1182/blood.2022015790. View

Molteni E, Bono E, Galli A, Elena C, Ferrari J, Fiorelli N . Prevalence and clinical expression of germ line predisposition to myeloid neoplasms in adults with marrow hypocellularity. Blood. 2023; 142(7):643-657. PMC: 10644067. DOI: 10.1182/blood.2022019304. View

Godley L, Shimamura A . Genetic predisposition to hematologic malignancies: management and surveillance. Blood. 2017; 130(4):424-432. PMC: 5533201. DOI: 10.1182/blood-2017-02-735290. View

Tsai F, Lindsley R . Clonal hematopoiesis in the inherited bone marrow failure syndromes. Blood. 2020; 136(14):1615-1622. PMC: 7530647. DOI: 10.1182/blood.2019000990. View

Ogawa S . Genetics of MDS. Blood. 2019; 133(10):1049-1059. PMC: 6587668. DOI: 10.1182/blood-2018-10-844621. View

Kennedy A, Shimamura A . Genetic predisposition to MDS: clinical features and clonal evolution. Blood. 2019; 133(10):1071-1085. PMC: 6405331. DOI: 10.1182/blood-2018-10-844662. View

Hirabayashi S, Wlodarski M, Kozyra E, Niemeyer C . Heterogeneity of GATA2-related myeloid neoplasms. Int J Hematol. 2017; 106(2):175-182. DOI: 10.1007/s12185-017-2285-2. View

10.

Feurstein S, Godley L . Germline ETV6 mutations and predisposition to hematological malignancies. Int J Hematol. 2017; 106(2):189-195. DOI: 10.1007/s12185-017-2259-4. View

11.

Noris P, Favier R, Alessi M, Geddis A, Kunishima S, Heller P . ANKRD26-related thrombocytopenia and myeloid malignancies. Blood. 2013; 122(11):1987-9. DOI: 10.1182/blood-2013-04-499319. View

12.

Polprasert C, Schulze I, Sekeres M, Makishima H, Przychodzen B, Hosono N . Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. Cancer Cell. 2015; 27(5):658-70. PMC: 8713504. DOI: 10.1016/j.ccell.2015.03.017. View

13.

Narumi S, Amano N, Ishii T, Katsumata N, Muroya K, Adachi M . SAMD9 mutations cause a novel multisystem disorder, MIRAGE syndrome, and are associated with loss of chromosome 7. Nat Genet. 2016; 48(7):792-7. DOI: 10.1038/ng.3569. View

14.

Chen D, Below J, Shimamura A, Keel S, Matsushita M, Wolff J . Ataxia-Pancytopenia Syndrome Is Caused by Missense Mutations in SAMD9L. Am J Hum Genet. 2016; 98(6):1146-1158. PMC: 4908176. DOI: 10.1016/j.ajhg.2016.04.009. View

15.

Tesi B, Davidsson J, Voss M, Rahikkala E, Holmes T, Chiang S . Gain-of-function mutations cause a syndrome of cytopenia, immunodeficiency, MDS, and neurological symptoms. Blood. 2017; 129(16):2266-2279. PMC: 5399482. DOI: 10.1182/blood-2016-10-743302. View

16.

Rudelius M, Weinberg O, Niemeyer C, Shimamura A, Calvo K . The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia. Virchows Arch. 2022; 482(1):113-130. DOI: 10.1007/s00428-022-03447-9. View

17.

Genovese G, Kahler A, Handsaker R, Lindberg J, Rose S, Bakhoum S . Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371(26):2477-87. PMC: 4290021. DOI: 10.1056/NEJMoa1409405. View

18.

Mitchell E, Spencer Chapman M, Williams N, Dawson K, Mende N, Calderbank E . Clonal dynamics of haematopoiesis across the human lifespan. Nature. 2022; 606(7913):343-350. PMC: 9177428. DOI: 10.1038/s41586-022-04786-y. View

19.

Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman P, Mar B . Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014; 371(26):2488-98. PMC: 4306669. DOI: 10.1056/NEJMoa1408617. View

20.

Ahmad H, Jahn N, Jaiswal S . Clonal Hematopoiesis and Its Impact on Human Health. Annu Rev Med. 2022; 74:249-260. DOI: 10.1146/annurev-med-042921-112347. View